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Abstract: Gastrointestinal stromal tumors (GIST) carrying the D842V activating mutation in the
platelet-derived growth factor receptor alpha (PDGFRA) gene are a very rare subgroup of GIST
(about 10%) known to be resistant to conventional tyrosine kinase inhibitors (TKIs) and to show an
indolent behavior. In this study, we performed an integrated molecular characterization of D842V
mutant GIST by whole-transcriptome and whole-exome sequencing coupled with protein–ligand
interaction modelling to identify the molecular signature and any additional recurrent genomic
event related to their clinical course. We found a very specific gene expression profile of D842V
mutant tumors showing the activation of G-protein-coupled receptor (GPCR) signaling and a relative
downregulation of cell cycle processes. Beyond D842V, no recurrently mutated genes were found
in our cohort. Nevertheless, many private, clinically relevant alterations were found in each tumor
(TP53, IDH1, FBXW7, SDH-complex). Molecular modeling of PDGFRA D842V suggests that the
mutant protein binds imatinib with lower affinity with respect to wild-type structure, showing higher
stability during the interaction with other type I TKIs (like crenolanib). D842V mutant GIST do
not show any actionable recurrent molecular events of therapeutic significance, therefore this study
supports the rationale of novel TKIs development that are currently being evaluated in clinical studies
for the treatment of D842V mutant GIST.
Int. J. Mol. Sci. 2018, 19, 732; doi:10.3390/ijms19030732 www.mdpi.com/journal/ijms
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1. Introduction
Approximately 80% of gastrointestinal stromal tumors (GIST) carry pathogenic activating
mutations of proto-Oncogene c-Kit (KIT), while 5% to 10% harbor activating mutations of the
platelet-derived growth factor receptor alpha (PDGFRA), both members of the type III class of
tyrosine kinase receptors [1–3]. The use of KIT/PDGFRA tyrosine kinase inhibitors (TKIs; imatinib,
sunitinib, and others) has revolutionized the medical treatment of GIST patients. It is known
that the sensitivity to TKIs is strictly correlated with the various types of KIT/PDGFRA mutations,
with the longest progression-free and overall survival associated to patients whose GIST harbors
exon 11 mutations [4–9]. Among PDGFRA mutant GIST, different mutations have been described
with a variable spectrum of sensitivity to TKIs. Some PDGFRA mutations (e.g., V561D or deletion
DIMH842-845) are associated to a clear sensitivity to imatinib in vitro and in clinical studies,
whereas other alterations confer treatment resistance in vitro (e.g., PDGFRA D842V, PDGFRA D842Y,
or PDGFRA DI842-843IM) [4,6,8,10–12]. The most common PDGFRA mutation is the exon 18 D842V,
which is fully resistant to imatinib and sunitinib [9,10]. Patients with metastatic/advanced D842V
mutant GIST do not benefit from standard TKIs therapy with a median progression-free survival of
2.8 months with imatinib and a median overall survival of 12.7 months [13]. Recently, a promising
anti-proliferative activity of crenolanib, an orally available selective and potent inhibitor of PDGFRA
and PDGFRB, was reported [14]. In vitro studies showed that crenolanib was at least 100-fold more
potent than imatinib on PDGFRA D842V kinase and other imatinib-sensitive and imatinib-resistant
PDGFRA mutant kinases (D842I, D842V, D842Y, DI842-843IM, and deletion I843). Moreover, crenolanib
interferes with the KIT signaling loop by down-regulation of ETV1 in GIST cells lines [15]. In phase I
clinical studies on advanced solid tumors, crenolanib showed a good tolerability [16,17]. Therefore,
crenolanib could be useful for the treatment of patients with GIST, and in particular those with PDGFRA
mutant GIST. Clinical studies of crenolanib are now ongoing (Randomized Trial of Crenolanib in
Subjects with D842V Mutated GIST—ClinicalTrials.gov Identifier: NCT02847429). However, currently
there are no effective, approved treatments available for patients with PDGFRA D842V mutant GIST.
The goal of our work was to examine the molecular background of primary and metastatic D842V
mutant GIST using whole transcriptome (RNA-seq) and whole exome sequencing (WES) analysis,
in order to describe the molecular signature and to pinpoint any additional genomic event potentially
relevant for the treatment of these patients.
2. Results
The molecular characterization of D842V mutant GIST was performed by exploring both RNA-seq
and WES together. The study involved a total number of 19 tumor samples, obtained from 14 unique
patients with PDGFRA D842V mutant GIST, all analyzed by WES. A subgroup of five out of the
19 tumors were also investigated with whole transcriptome sequencing (Table 1).
In particular, we included eight primary tumors (among which are the five tumors analyzed by
RNA-seq), 10 metastases, and one tumor of unknown source. All the primary GIST were naive to
any treatment, while the metastases were taken from patients previously treated with one or with
combinations of Tyrosine Kinase Inhibitors (TKIs) before surgery (only one of the metastases was also
treated with chemotherapy).
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Table 1. Patients and Tumor Samples.
Patient Sample Age at Surgery Sex Type of Sample Primary Tumor Location Tumor Size Mitotic Index 50HPF Source Treatment Before Sampling WES RNA-Seq
P01 T01 62 M Frozen stomach 11 300 metastasis C, D 101X1 NA
P02 T02 74 F Frozen stomach 16.2 5 metastasis C 101X1 NA
P03 T03 51 M Frozen stomach 5 55 metastasis I, G/D, Su, IPI-504, So, STA-9090,D, GDC-0980, C 101X1 NA
P04
T04 51 M FFPE stomach 6.2 7 metastasis none 101X1 NA
T05 51 M FFPE stomach 6.2 7 metastasis none 101X1 NA
P05 T06 53 M Frozen OCT NA NA NA primary none 101X1 NA
P06
T07 56 M FFPE stomach 30 high metastasis I, Su, So, N 101X1 NA
T08 56 M FFPE stomach 30 high metastasis I, Su, So, N 101X1 NA
T09 56 M FFPE stomach 30 high metastasis I, Su, So, N 101X1 NA
T10 56 M FFPE stomach 30 high metastasis I, Su, So, N 101X1 NA
T11 56 M FFPE stomach 30 high metastasis I, Su, So, N 101X1 NA
P07 T12 63 F Frozen stomach 10.5 19 NA C 101X1 NA
P08 T13 76 M Frozen stomach NA NA primary none 101X1 NA
P09 T14 30 M Frozen stomach NA NA primary none 101X1 NA
P10 T15 50 F Frozen stomach 1.8 2 primary none 100X2 75X2
P11 T16 75 F Frozen stomach 7 8 primary none 100X2 75X2
P12 T17 68 M Frozen stomach 3 5 primary none 100X2 75X2
P13 T18 76 M Frozen stomach 4.5 6 primary none 100X2 75X2
P14 T19 51 M Frozen stomach 12 2 primary none 100X2 75X2
WES, whole exome sequencing; FFPE, formalin-fixed paraffin-embedded; OCT, optimal cutting temperature; M, male; F, female (F); NA, Not Available; C, Crenolanib; D, dasatinib; I,
imatinib; N, nilotinib; So, sorafenib; Su, sunitinib; GD, gemcitabine/docetaxel ; STA-9090, ganetespib; GDC-0980, apitolisib; IPI-504, retaspimycin.
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2.1. Gene Expression Profile
Gene expression profiling (GEP) was performed by whole transcriptome sequencing to identify
specific molecular signatures of five GIST carrying PDGFRA D842V mutation (T15–19 corresponding to
five unique patients P10–14). To this end, D842V mutant RNA-seq data were compared to a set of seven
KIT mutant GIST. The principal component analysis showed a good overlap of the D842V mutant
tumors, which is a hallmark of a very homogeneous molecular profile. This is less evident for the KIT
mutant tumors, nevertheless we were able to appreciate a discrete spatial separation between the two
molecular groups of GIST (Figure 1A), suggesting the presence of two distinct gene expression profiles.
Differential expression (DE) analysis identified 494 overexpressed and 144 downregulated genes in the
D842V mutant with respect to the KIT mutant GIST (p-value < 0.01) (Figure 1B). In order to characterize
the gene signature of up/downregulated genes, pathway enrichment analysis was performed using
Reactome database (https://reactome.org/)as the database resource (Figure 1C). Table 2 lists the top
10 significantly enriched and depleted pathways (full results are shown in Supplementary Table S1).
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Figure 1. Transcriptome profile of D842V mutant versus KIT mutant GIST. (A) Principal component 
analysis performed on the whole set of expressed genes (n = 15,134) shows a very uniform profile of 
D842V mutant tumors (red dots) that is distinctly separated from KIT mutant GIST (blue dots); (B) 
Heatmap of 494 overexpressed and 144 downregulated genes in D842V GIST; hierarchical clustering 
was performed to groups genes adopting Manhattan distance and Ward method; (C) Graphical 
representation of genes and pathways emerging as enriched (red) or depleted (green) in D842V 
mutant GIST. Genes and the corresponding pathways are also reported in Supplementary Table S2. 
We found that the pathways of G-protein-coupled receptor (GPCR) signaling, 
Glycosaminoglycan metabolism, Voltage-gated potassium channels (VGKCs), and Neurotransmitter 
Receptor Binding are significantly enriched in the D842V mutant group, while the cell cycle and 
DNA repair gene sets are enriched in the KIT mutant group. The GPCR signaling pathway includes 
the majority of leading edge genes. Among them, the most overexpressed genes in the D842V 
mutant are: Dopamine receptor D1 (DRD1, log2Ratio = 6.8, p-value = 0.00069); Somatostatine receptor 
1 (log2Ratio = 6.7, p-value = 0.00035); Neuropeptides B and W receptor 1 (NPBWR, log2Ratio = 6.6; 
p-value = 0.0066); and Cholecystokinin (CCK, log2Ratio = 5.7; p-value = 0.0021). We also highlighted 
quite a large set of chemokines (CCL19, CCL21, CCR2, CCR6, CCR7, CX3CR1) and prostaglandins 
Figure 1. Transcriptome profile of D842V mutant versus KIT mutant GIST. (A) Principal component
analysis performed on the whole set of expressed genes (n = 15,134) shows a very uniform profile
of D842V mutant tumors (red dots) that is distinctly separated from KIT mutant GIST (blue dots);
(B) Heatmap of 494 overexp essed a d 144 downregul te ge es i D842V GIST; hierarchical clustering
was performed to groups genes adopting Manhattan distance and Ward method; (C) Graphical
representation of genes and pathways emerging as enriched (red) or depleted (green) in D842V mutant
GIST. Genes and the corresponding pathways are also reported in Supplementary Table S2.
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Table 2. Reactome gene set enrichment performed with WebGestalt.
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We found that the pathways of G-protein-coupled receptor (GPCR) signaling, Glycosaminoglycan
metabolism, Voltage-gated potassium channels (VGKCs), and Neurotransmitter Rec ptor Binding are
significantly nriched in the D842V mutant group, while the cell cycle and DNA repair gene sets are
enriched in the KIT mutant group. The GPCR signaling pathway includes the majority of leading edge
genes. Among them, the most overexpressed genes in the D842V mutant are: Dopamine receptor D1
(DRD1, log2Ratio = 6.8, p-value = 0.00069); Somatostatine receptor 1 (log2Ratio = 6.7, p-value = 0.00035);
Neuropeptides B and W receptor 1 (NPBWR, log2Ratio = 6.6; p-value = 0.0066); and Cholecystokinin
(CCK, log2Ratio = 5.7; p-value = 0.0021). We also highlighted quite a large set of chemokines (CCL19,
CCL21, CCR2, CCR6, CCR7, CX3CR1) and prostaglandins (PTGDR, PTGER4, PTGIR) that contribute to
the enrichment of GPCR signaling pathway. On the contrary, the cell cycle pathway contains a large
number of downregulated genes in the D842V tumors such as the minichromosome maintenance
complex genes (MCM family), polymerase genes (POLE, POLD2) and cyclin-dependent kinase (CDK1,
CDK2, CDKN1A).
2.2. Fusion Transcript by Whole Transcriptome Sequencing
To further define the transcriptional profile of D842V mutant tumors, we also looked for chimeric
transcripts through RNA-seq data. The consensus method highlighted a total of 13 fusion genes in the
five tumors analyzed (Supplementary Table S3). We found two recurrent chimeras (POLA2-CDC42EP
and CTSC-RAB38) that did not support any chromosomal rearrangement since they derive from
non-pathological read-through transcription. Notably, the large majority of the detected fusion genes
(more than 90%) correspond to read-through or conjoined genes that are probably not disease-related.
Only one intra-chromosomal rearrangement on chromosome 14 in the tumor T17 was detected (one of
the tumors in which chromosome 14 deletion were identified by WES). In particular, two different
gene fusion detection algorithm predicted a breakpoint sequence between the 5′UTR of C14orf159 and
the exon 2 of MGDA2 (Ensembl v91: ENSE00003707948), either leading to the loss of start codon of
MGDA2 in the isoforms carrying that exon as a coding component or allowing the MGDA2 expression
under the control of the C14orf159 promoter (for the other isoforms). However, the low depth of
coverage at breakpoint level and the very poor expression of MGDA2 suggest that the gene fusion is
not functionally relevant.
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From a global point of view, the very low rate of chromosomal aberrations leading to chimeric
transcripts suggests that D842V tumors have a rather stable genome.
2.3. Whole Exome Sequencing
To better investigate the mutational burden of the D842V mutant GIST, we performed the WES
analysis on 19 tumor samples and on the matched normal counterpart. Five of the 19 samples were
analyzed with the paired-end 100 × 2 approach, while sequencing of the remaining 14 samples was
performed with a single-single end strategy at 101bp for a total of 197 Gb (Giga bases), thus leading
to an average number of mapped reads per sample of 55 × 106, with an average depth of coverage
of 60×.
A total of 316 high-confidence somatic rare variants were found, including coding single
nucleotide variants (SNVs), frameshift and non-frameshift insertions and deletions (InDels),
and variants at ±3 on the splice sites (average = 17, min–max = 3–26) (Supplementary Table S4).
Mutational burden was calculated and reported in Figure 2. Most of the samples show a low
degree of somatic mutations per Mb of captured coding exome ~0.5, which is comparable to the
mutational load of chronic lymphocytic leukemia (CLL), neuroblastoma, and glioblastoma. Moreover,
two samples (T06 and T14) showed a very low mutational load, similar to acute lymphocytic leukemia
(ALL) and medulloblastoma [18]. However, comparing WES data with RNA-seq, we estimated that
only one-third of genes carrying somatic SNVs or InDels were actually expressed in tumor cells.
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Figure 2. Mutational burden of D842V mutant GIST. The histogram bars indicate the number of somatic
mutations per magabases (Mb) of coding region.
The only recurrent somatic mutation was located on exon 18 of PDGFRA, and corresponded
to the expected D842V previously identified by molecular testing procedures. Beyond PDGFRA
mutations, the results showed three other significantly mutated genes: the transmembrane protein
TMEM140, the TEA Domain Transcription Factor 2 (TEAD2), and the Olfactory Receptor Family
1 Subfamily J Member 2 (OR1J2). All the three mutated genes were recurrent in five of the
19 samples that correspond to five geographically distinct metastases of the same patient (samples
T07–11 corresponding to patient P06). Although not significantly represented, somatic mutations
of GRIN2B (Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2B) were found in two different
samples (N622D on T06, and V42L on T07). Together with TMEM140, TEAD2, OR1J2, and GRIN2B,
many other genes were commonly mutated across the tumor samples, however the recurrence always
occurred when examining multiple metastatic samples of the same individual (T07–11 or T04–05
corresponding respectively to patients P06 and P04). For these multiple samples of metastasis
belonging to same individual, T07–11 (five metastases) and T04–05 (two metastases), the tumor
clonal evolution was also evaluated (Figure 3). All the other somatic events were private variants
that we can consider as passenger mutations. All the genes with somatic variants were matched with
the TARGET database (tumor alterations relevant for genomics-driven therapy—Available onlines:
http://archive.broadinstitute.org/cancer/cga/target). By this, we identified three potentially relevant
alterations: the Y272C on IDH1 (T02), the R465H on FBXW7 (T07–11), and two different mutations
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on TP53 (c.993 + 1G > A at exon 10 splice site and a C135G) on sample T13. Moreover, one tumor
sample (T06) showed the somatic mutation T60A in the Succinate Dehydrogenase Complex Subunit
B (SDHB), and interestingly the same patient also carried the R38P germline variant in the subunit
D of the same complex (SDHD). Both variations on SDH complex genes were previously reported
in the archive of ClinVAr (https://www.ncbi.nlm.nih.gov/clinvar/) as germline variants in GIST,
hereditary paraganglioma, and pheochromocytoma. In particular, the T60A in SDHB was annotated as
a single nucleotide variant of uncertain significance, while the R38P in SDHD was widely described
as pathogenic.
Copy number alterations were assessed from WES data (Figure 4). We confirmed the commonly
known regions of losses in GIST located on chromosome 1, 14, and 22, and we found at least one of
these aberrations in ~90% of tumor samples (corresponding to all patients except P05). Moreover,
the analysis also showed the loss of chromosome 4, loss of the short arms of chromosomes 7 and
9, and loss of the long arms of chromosomes 15 and 21. In addition, a focal deletion of dystrophin
gene (DMD) on chromosome X was found in 42% of tumor samples (corresponding to four patients:
P03, P06, P07, and P08). This particular aberration is known to be associated with the metastatic
tumors [19,20] even if in our series this evidence is not statistically significant due to the small number
of samples. We found also numerous copy number gains (in particular on chromosomes 5, 7, 8, 17, and
19) that, interestingly, occurred mostly in metastatic samples.Int. J. Mol. Sci. 2018, 19, x  8 of 17 
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2.4. In Silico Modeling
Beyond the whole transcript and whole exome characterization, and due to the absence of other
driver molecular events in this GIST subgroup, we investigated the efficacy of the D842V substitution
at the protein level, with the aim to define the role of this oncogenic alteration within the peptidic
sequence. The single amino acid substitution of aspartic acid with valine at 842 position (D842V) is
known to be associated with the resistance to first-line and second-line tyrosine kinase inhibitors (such
as imatinib and sunitinib). Since the crystallized structure of the tyrosine kinase domain of PDGFRA
(corresponding to the intracellular C-terminal part of the protein, Figure 5A) was recently released
(PDB: 5K5X) [21], a protein structure model was created specifically for the D842V mutant and the
structure of the complex c-Kit–imatinib (PDB: 1T46) was also aligned in order to ligand imatinib within
the PDGFRA structure (Figure 5B).
The mutation D842V is found in the activation loop, known to contain a conserved motif
Asp836-Phe837-Gly83 (DFG) that may assume the “in” or “out” conformations corresponding to
the active and inactive state of the PDGFRA kinase domain, respectively [21].
X-ray crystallographic studies of protein–ligand interactions demonstrated that imatinib binds to
the inactive (DFG-out) conformation of the Type III transmembrane receptor protein tyrosine kinase
(RPTK) subfamily including c-Kit and PDGFRA [22]. Our model also predicts that that the mutation
D842V leads to the loss of polar interactions involving the residues His845, Ile843, Met844, and Asp846
(Figure 5C,D) that are essential for the stability of the activation loop and to stabilize the DFG-out
active conformation. The result is the switch from the DFG-out to the DFG-in conformation activating
the kinase, making imatinib incapable of binding to the receptor.
To better understand the molecular basis for the enhanced efficacy of crenolanib versus imatinib
against the PDGFRA D842V mutant kinase, we simulated the binding of crenolanib to the modeled
PDGFRA in DFG-in conformation. In silico analysis revealed eight different docking clusters of
crenolanib at the ATP binding site, and the top scoring docked model was selected (Figure 5E).
The docking simulation suggests that crenolanib targets the active conformation of tyrosine kinase
subunit of PDGFRA, in which the activation loop is phosphorylated, binding the ATP active residues
without involving the adjacent allosteric site that is available only in the inactive conformation (suitable
for the type II kinase inhibitors like imatinib and sunitinib) [23].
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wild-type Aspartic Acid; (D) Polar interactions of the 842 residue carrying the mutated Valine amino
acid; (E) Representation of the best docked pose of crenolanib in the PDGFRA ATP binding site.
3. Discussi n
GIST harboring PDGFRA exon 18 D842V are fully resistant to imatinib and sunitinib [9,10].
To date, no approved effective treatments are available for these patients. In addition, no additional
molecular events potentially relevant as therapeutic targets are known to be associated with this GIST
molecular subtype.
In this study, primary and metastatic D842V mutant GIST were investigated by exploring
RNA-seq,WES and molecular modelling adopting a top-down approach. First, whole transcriptome
data were analyzed to take a picture of the molecular profile and identify specific signatures of GIST
with D842V mutation. Second, each tumor in the D842V mutant cohort was analyzed independently
to highlight molecular aberrations such as chromosomal rearrangements (from RNA-seq data), point
mutations, and copy number variants (from WES). Lastly, the D842V alteration at the protein level was
studied by molecular modelling.
Whole transcriptome analysis showed a very characteristic expression profile of D842V mutant
GIST when they are compared with other molecular subgroups of GIST (KIT mutant in our case).
In particular, our results highlighted the overexpression of many genes leading to the activation of
GPCR signaling. Among these, we noticed genes that suggest a neural differentiation of D842V
tumors such as DRD1, SSTR1, NPBWR1, and CCK. Moreover, it is known that GIST express
somatostatin receptors [24] and that SSTR1 was widely reported [25] as expressed in the better
differentiated gastroenteropancreatic neuroendocrine tumors and associated with a good prognosis.
This was suggested also in GIST samples, at least for other somatostatin receptors such as SSTR2 and
SSTR5. [24]. This observation, together with a relative downregulation of cell cycle promoting genes,
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could explain at least in part the clinical evidence of an indolent disease course of D842V mutant GIST
with respect other subgroups. The downregulation of cell cycle and DNA repair pathways in the
D842V mutant GIST is also important, considering a recent study in which the impairment in these
signaling paths was associated with a better response to chemotherapeutic DNA-damaging agents in
imatinib-resistant GIST cell lines [26]. Moreover, the upregulation of chemokine and prostaglandin
may be a clue of a possible role of tumor microenvironment, and it could suggest the D842V mutant
tumor immunogenicity.
Whole exome analysis showed that no actionable molecular events in this population and
confirmed that the only recurrent somatic exomic mutation was the D842V. Many other genes variants
were found but were determined to be private genetic events.
Notably, additional molecular events such as mutations in TMEM140 and TEAD2 were found to
be shared in all the five geographically distinct tumor specimens obtained from the same individual.
TMEM140 over-expression was strongly correlated with tumor size, histologic grade, and overall
survival time in patients with gliomas [27]. Therefore, TMEM140 has been proposed as a novel
prognostic marker and as a potential therapeutic target for gliomas. TEAD2 belongs to the protein
family that may interact with transcription factors and may play a key role in cancer progression by
regulating apoptosis and cell proliferation [28]. Even though the biological functions of TMEM140 and
TEAD2 seem relevant in cancer development and progression, in D842V mutant GIST these proteins
were found mutated in only one patient and therefore no definitive conclusion can be realistically
drawn. In addition, GRIN2B was mutated in two different samples but this event seems irrelevant in
cancer biological processes.
Other relevant events, even though private, emerged by the comparison of the mutated genes
with the TARGET archive. In particular, the IDH1 gene shows a Y272C somatic variant; this gene is
known to be frequently mutated in glioma, cholangiocarcinoma, chondrosarcoma, and acute myeloid
leukemia, but in those diseases the recurrent mutations is a gain-of-function point mutation at arginine
132. The functional significance of the Y272C mutation is unknown. Conversely, the alteration on
FBXW7 (R465H) is one of the hot-spot mutations previously reported in a large number of different
carcinomas and leukemias. However, this alteration is known to confer resistance to specific inhibitors.
Finally, we also found biallelic inactivation of tumor suppressor TP53, but this mutation is not
currently targetable.
Additionally, one tumor sample (T06) harbored a somatic mutation T60A of SDHB, and interestingly
the same patient carried the germline variant R38P in SDHD. SDHB and SDHD are two subunits of the
SDH complex that correspond to the enzyme complex II of the mitochondrial respiratory chain. As is
well known, loss of function mutations in these genes are known to characterize the SDH-deficient
GISTs lacking PDGFRA and KIT mutations in the context of Carney Triad or Carney–Stratakis syndrome
or sporadic young adult KIT/PDGFRA wild-type GIST, thus mutations in any SDH gene are known to
be mutually exclusive with KIT and PDGFRA [29,30]. Recently, one case report showed a patient with
D842V mutation that, in addition, harbored two loss of function mutations (germline and somatic) in
SDHB and the tumor was confirmed as SDH-deficient [31]. Moreover, two case reports are available
on patients that harbor mutations in KIT receptor in a context of a Carney–Stratakis syndrome in
which GIST are supposed to be KIT/PDGFRA wild type [32,33]. However, in our case reported here,
the SDHB protein expression was not evaluated by immunohistochemistry (IHC) test, so we do not
know if these two mutations in SDHB and SDHD lead to a loss of function of SDH complex.
A percentage of 42% of samples (corresponding to four unique patients) showed a focal deletion
of dystrophin gene (on chromosome X). Deletions of dystrophin in KIT/PDGFRA mutant GIST have
been previously reported and usually are associated with more advanced clinical stages of disease
such as metastatic tumors [19,20]. In this study, the deletion of DMD occurred mainly in tumors with a
high mitotic index of the primary tumor and in metastatic lesions.
Another relevant point is that none of the analyzed samples, differently from KIT mutant
GIST, showed secondary mutations in PDGFRA, neither naïve (n = 9) nor treated patients (n = 5).
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This observation suggests that the ineffectiveness of drug treatments with type II tyrosine kinase
inhibitor is not due to resistance acquisition consequent to the therapy, but indicates this subgroup of
GIST are ab initio refractory tumors in which the mechanism of resistance is exclusively related to the
primary driver mutation D842V.
Finally, the main finding of this study remains the key role of D842V mutation in this GIST sub
population as the main and only relevant event of cancer development. These confirming findings
highlight the importance on the development of drugs such as crenolanib that directly inhibit the
D842V kinase. By in vitro studies, crenolanib proved to act at least as a 100-fold more potent inhibitor
than imatinib on PDGFRA D842V kinase and showed a good tolerability profile in phase I clinical
studies on advanced solid tumors [14,16,17]. A phase II study was recently completed to evaluate
the antitumor efficacy and pharmacokinetics of crenolanib in patients with D842V mutant GIST,
and a phase III trial of crenolanib versus placebo in combination with best supportive care in patients
with D842V mutant GIST is now ongoing. To reinforce the proof of principles of these studies, our in
silico modeling study revealed eight different docking clusters of crenolanib at the ATP binding site.
Crenolanib binds active residues without involving the adjacent allosteric site that is available only
in the inactive conformation (suitable for the type II kinase inhibitors like imatinib and sunitinib).
This suggests that crenolanib targets the active conformation of the tyrosine kinase subunit of PDGFRA
in which the activation loop is phosphorylated. Therefore, patients carrying this mutation should
be considered for treatment with a type I tyrosine kinase inhibitor that targets the ATP binding site
when the kinase is in the active conformation. In conclusion, in our series of D842V mutant GIST,
we did not identify any additional molecular events associated to cancer development that could
be considered as potential therapeutic targets. Crenolanib, or other type I tyrosine kinase inhibitors
such as BLU-285 [34], should be considered for the treatment of patients with D842V mutant GIST,
and further and definitive studies on this approach in clinical settings are expected.
4. Materials and Methods
This study was approved by the local institutional ethical committee of Azienda
Ospedaliero-Universitaria Policlinico S.Orsola-Malpighi (approval number 113/2008/U/Tess,
30 September 2008 approval code, approval date). All patients provided written informed consent.
Fresh tissues snap-frozen in liquid nitrogen and stored at −80 ◦C (FF) or formalin-fixed
paraffin-embedded (FFPE) specimens of PDGFRA mutant GIST were used for the whole exome
analyses. All primary tumors were localized in the stomach, although metastatic tumor samples were
analyzed in ~50% of cases. The tumor and patient’s characteristics are reported in Table 1.
Whole Exome Sequencing (WES) was performed on 19 tumor samples previously characterized
as harboring PDFGRA D842V mutations, and on matched normal counterpart (peripheral blood or
stomach). The 19 tumors collected belong to 14 unique patients: 12 patients with one single tumor
sample, one patient with two samples (T04 and T05 corresponding to patient P04), one patient with five
samples (T07, T08, T09, T10, and T11 corresponding to patient P06). For both patients (P04 and P06),
the multiple samples analyzed correspond to different geographically distinct specimens available.
Additionally, whole transcriptome analysis was performed on five of the above mentioned samples
(T15, T16, T17, T18, T19).
4.1. Whole-Transcriptome Paired-End RNA Sequencing and Whole Exome-Sequencing
Total RNA was extracted from tumor specimens with RNeasy Mini Kit (Qiagen, Milan, Italy),
then cDNA libraries were synthesized from 250 ng total RNA with TruSeq RNA Sample Prep Kit v2
(Illumina, San Diego, CA, USA) according to the manufacturer’s recommendations. Sequencing
by synthesis was performed on HiScanSQ sequencer (Illumina) at 75 bp in paired-end mode.
Whole-transcriptome sequencing yielded a total of 32 Giga Bases and an average of 84 millions
of short reads with an average depth of coverage of 45×
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WES was performed on DNA isolated from fresh frozen and FFPE tumor tissue and from matched
normal peripheral blood or stomach DNA. Whole exome libraries were prepared applying different
protocols and using two different sequencing platforms: Nextera Rapid Capture Exome Enrichment
(Illumina) was adopted on five out of 19 samples that were sequenced on Illumina HiScanSQ at
2 × 100 bp read length; eight out of 19 libraries were prepared with Nimblegen SeqCap v02 (Roche,
Pleasanton, CA, USA), and six out of 19 with Nimblegen SeqCap v03 (Roche, Pleasanton, CA, USA)
and were run on HiSeq2000 Illumina platform at 100 bp in single-end. For all the three capturing
systems, the exome enrichment was performed according to manufacturer’s protocols.
4.2. Bioinformatic Analysis
Data analysis was performed on local server CentOS5 Linux, adopting a customized full open
source bioinformatic pipeline.
After the conversion from bcl to fastq format, the short reads were processed to clean up from
sequencing adapters, and to filter or trim the reads for sequence quality (minimum Phred quality
of 10 and minimum length of trimmed sequence of 30). Both these steps were performed with
AdapterRemoval v.1.5.4 tool [35], after which the cleaned reads were mapped on human reference
genome hg19 with Burrows–Wheeler Aligner (BWA v0.7.12) [36] for WES data, in paired-end or
single-end mode according to the type of sample, and with the TopHat/Bowtie v2.0.9 [37] pipeline for
RNA-seq data. Samtools v1.4 [38] was adopted to remove the optical and PCR duplicates and to index
the alignment files. Then, the RNA-seq data analysis was performed to examine for the presence of
any chromosomal rearrangements leading to gene fusions. For this purpose, four different tools were
adopted: TopHat-Fusion v.2.0.9 [39], Defuse v0.6.2 [40], ChimeraScan v0.4.5 [41], FusionMap v2015 [42].
In order to increase the specificity, a predicted gene fusion was considered for further investigation if it
was detected at least by two of four predictors. Gene expression profiling and differential expression
of D842V mutant was evaluated comparing them with a set of seven GIST tumors with mutation
on KIT exon 11 as previously described by Nannini et al. (2014) [43], and the pathway enrichment
analysis was performed with WEB-based GEne SeT AnaLysis Toolkit (www.webgestalt.org) adopting
the Reactome functional database (https://reactome.org/) as reference and the default settings of the
tool. This analysis was run on the pre-ranked gene list of 1882 differentially expressed genes, selected
by soft filtering cut-off (p < 0.05 and |log2Ratio| < 0.4).
The whole exome data were then analyzed with the aim to detect point mutations and copy
number variations. First, the realignment around insertions and deletions (InDels) and the base
quality recalibration were performed with Genome Analysis Toolkit v3.3-0 (GATK) [44]. For WES
tumor samples, Mutect v1.1.7 [45] and GATK v3.3-0 (HaplotypeCaller function) were then used to
call the single nucleotide variants (SNVs) and InDels respectively, adopting the default parameters
for both algorithms. Among the whole set of called variants, we selected those with total depth
> 10, Ratio > 0.2 (ratio between the depth of coverage of the alternate event and the total depth
of coverage), present within coding exons and having a non-silent effect on protein sequence
(non-synonymous and nonsense SNVs, frameshift and non-frameshift InDels). The alterations
were filtered on databases of human variability (dbSNP: https://www.ncbi.nlm.nih.gov/SNP/),
1000Genomes: http://www.internationalgenome.org/; EVS: http://evs.gs.washington.edu/EVS/;
ExAC: http://exac.broadinstitute.org/) in order to discard polymorphism and keep novel or very
rare variants (population frequency < 0.01). All the gene-based and filter-based annotation steps
were performed with Annovar v2015Jun16 software tool [46] with the provided database. Finally,
the resulting list of variants were distinguished between somatic or germline by calling the alternate
events on the normal counterpart alignments using Samtools v1.4 mpileup function and assuming the
following criteria: total depth > 5, depth of altered base = 0 (depth = 1 or depth = 2 were allowed if the
total depth was ≥15 or ≥30 respectively) to include the variant in the “somatic” set. Otherwise we
marked the events as “germline”, or “undetermined” if the total coverage on the normal counterpart
was considered not sufficiently informative (total depth < 5). The somatic variants were handled with
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SnpSift dbNSFP v4.1 [47], an integrated database of functional computational tools to predict the
alteration effects of on protein function and stability.
Moreover, on paired tumor/normal WES data, the analysis of amplifications and large deletions
was performed applying two different tools, Control FREEC v7.2 [48] and ADTEX v2.0 [49].
A consensus method was implemented with the aim of selecting the overlapping regions given
by the two algorithms (overlap of gain or loss ≥ 80%) followed by a downstream filtering procedure
that takes into account the uncertainty value given by Control FREEC (uncertainty < 80%). Finally, the
Database of human Genomic Variants (http://dgv.tcag.ca/dgv/app/home) was adopted to filter out
the polymorphic copy number variants.
The 3D structure of PDGFRA D842V mutant was built with Modeller v9.8 [50] using the Protein
Data Bank (PDB: https://www.rcsb.org/) crystal of tyrosine kinase domain of human PDGFRA (PDB:
5K5X). Chimera v1.11.2 [51] was adopted to visualize the model and to compare it with the wild-type
structure by distance analyses (Structure Analysis—Distance function). The Imatinib–Kit human
structure (PDB: 1T46) was also aligned to the PDGFRA mutant with the function MatchMaker.
The 3D model of the human PDGFRA in its active conformation was built by adopting the Kinase
domain of KIT in the active conformation (PDB: 1PKG) as a template (sequence identity of 61%).
After the generation of pairwise alignment using ClustalW2 (https://www.ebi.ac.uk/Tools/msa/
clustalw2/) [52], 20 different models were computed with Modeller v9.8, and Discrete Optimized
Protein Energy function was evaluated with the aim to select the lowest energy structure.
The Rigid Molecular Docking of crenolanib to the modeled PDGFRA was performed with
Autodock v4.2 [53]. The ligand (Crenolanib) coordinates were generated with PRODRG server [54]
and five active torsion angles were set. The 3D grid box (dimensions 60 × 60 × 60 unit in number of
grid points; grid spacing 0.375 Å) centered into the kinase ATP binding pocket was then created using
autogrid v4.2. A total of 1500 runs of Lamarckian genetic algorithm were performed, with an initial
population of 300 conformations, a cutoff of 27,000 generations, and with rates of mutation and
crossover set to 0.02 and 0.8, respectively. The final solution was characterized by the lowest
binding energy.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/3/
732/s1.
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